blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3782995

EP3782995 - SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES [Right-click to bookmark this link]
Former [2021/08]HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF
[2023/25]
StatusThe patent has been granted
Status updated on  20.10.2023
Database last updated on 02.09.2024
FormerGrant of patent is intended
Status updated on  06.06.2023
FormerExamination is in progress
Status updated on  02.09.2022
FormerRequest for examination was made
Status updated on  22.01.2021
FormerThe international publication has been made
Status updated on  25.10.2019
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): IT, SK		published on 04.09.2024 [2024/36]
Applicant(s)For all designated states
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
555 Zu Chong Zhi Road
Zhang Jiang
Pudong, Shanghai 201203 / CN
For all designated states
Suzhou Institute of Materia Medica
108 Yuxin Road
Suzhou Industrial Park
Suzhou, Jiangsu 213000 / CN
[2023/44]
Former [2021/08]For all designated states
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
555 Zu Chong Zhi Road
Zhang Jiang
Pudong, Shanghai 201203 / CN
For all designated states
Suzhou Institute of Drug Innovation, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
108 Yuxin Road, Suzhou Industrial Park
Suzhou, Jiangsu 213000 / CN
Inventor(s)01 / ZHOU, Bing
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
02 / LUO, Cheng
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
03 / JIANG, Hualiang
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
04 / YANG, Yaxi
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
05 / MEI, Lianghe
108 Yuxin Road, Suzhou Industrial Park
Suzhou, Jiangsu 213000 / CN
06 / LU, Wenchao
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
07 / XIAO, Senhao
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
08 / CHEN, Shijie
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
09 / WAN, Shili
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
10 / QIAO, Gang
108 Yuxin Road, Suzhou Industrial Park
Suzhou, Jiangsu 213000 / CN
11 / ZHANG, Rukang
555 Zu Chong Zhi Road, Zhang Jiang, Pudong
Shanghai 201203 / CN
 [2021/08]
Representative(s)Bandpay & Greuter
11 rue Christophe Colomb
75008 Paris / FR
[N/P]
Former [2021/08]Bandpay & Greuter
30, rue Notre-Dame des Victoires
75002 Paris / FR
Application number, filing date19788657.518.04.2019
[2021/08]
WO2019CN83190
Priority number, dateCN20181036007820.04.2018         Original published format: CN201810360078
CN2018111272431.08.2018         Original published format: CN201811012724
[2021/08]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019201291
Date:24.10.2019
Language:ZH
[2019/43]
Type: A1 Application with search report 
No.:EP3782995
Date:24.02.2021
Language:EN
[2021/08]
Type: B1 Patent specification 
No.:EP3782995
Date:22.11.2023
Language:EN
[2023/47]
Search report(s)International search report - published on:CN24.10.2019
(Supplementary) European search report - dispatched on:EP30.04.2021
ClassificationIPC:C07D403/06, C07D403/14, C07D413/06, C07D413/14, C07D417/06, C07D471/04, C07D471/10, C07D495/04, C07D495/10, C07D491/107, C07D498/04, C07D498/10, A61K31/4725, A61K31/55, A61K31/5513, A61K31/553, A61K31/554, A61P3/00, A61P25/28, A61P29/00, A61P35/00
[2023/25]
CPC:
C07D471/10 (EP); C07D413/06 (EP,CN,US); A61K31/4725 (EP);
A61K31/55 (EP); A61K31/5513 (EP); A61K31/553 (EP);
A61K31/554 (EP); A61K45/06 (EP,US); A61P25/28 (EP,CN);
A61P29/00 (EP,CN); A61P3/00 (EP,CN); A61P35/00 (EP,CN);
A61P35/02 (EP,CN); C07D401/14 (CN); C07D403/06 (EP,CN,US);
C07D403/14 (EP,CN,US); C07D413/14 (EP,CN,US); C07D417/06 (EP,CN,US);
C07D471/04 (EP,CN,US); C07D491/107 (EP,CN,US); C07D495/04 (EP,CN,US);
C07D495/10 (EP,US); C07D498/04 (EP,CN,US); C07D498/10 (EP,CN,US);
C07D513/04 (US); C07B2200/07 (CN) (-)
C-Set:
A61K31/4725, A61K2300/00 (EP);
A61K31/5513, A61K2300/00 (EP);
A61K31/553, A61K2300/00 (EP);
A61K31/554, A61K2300/00 (EP);
A61K31/55, A61K2300/00 (EP)
(-)
Former IPC [2021/08]C07D413/06, C07D417/06, C07D413/14, A61K31/4725, A61K31/55, A61K31/553, A61K31/554, A61K31/5513, A61P35/00, A61P35/02, A61P3/00, A61P25/28, A61P29/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/08]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:SPIRO KONDENSIERTE IMIDAZOLIN-2,4-DION DERIVATIVE ALS HISTON ACETYLTRANSFERASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBSERKRANKUNGEN[2023/25]
English:SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES[2023/25]
French:DÉRIVÉS D'IMIDAZOLINE-2,4-DIONE SPIRO EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE POUR LE TRAITEMENT DES MALADIES DE CANCER[2023/25]
Former [2021/08]HISTONACETYLTRANSFERASE(HUT)-INHIBITOR UND DESSEN VERWENDUNG
Former [2021/08]HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF
Former [2021/08]INHIBITEUR D'HISTONE ACÉTYLTRANSFÉRASE (HAT) ET UTILISATION ASSOCIÉE
Entry into regional phase17.11.2020Translation filed 
20.11.2020National basic fee paid 
20.11.2020Search fee paid 
20.11.2020Designation fee(s) paid 
20.11.2020Examination fee paid 
Examination procedure20.11.2020Examination requested  [2021/08]
26.11.2021Amendment by applicant (claims and/or description)
02.09.2022Despatch of a communication from the examining division (Time limit: M04)
06.01.2023Reply to a communication from the examining division
07.06.2023Communication of intention to grant the patent
10.10.2023Fee for grant paid
10.10.2023Fee for publishing/printing paid
10.10.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
30.04.2021Renewal fee patent year 03
31.03.2022Renewal fee patent year 04
31.03.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT22.11.2023
CZ22.11.2023
DK22.11.2023
EE22.11.2023
ES22.11.2023
HR22.11.2023
IT22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RO22.11.2023
RS22.11.2023
SE22.11.2023
SK22.11.2023
SM22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
[2024/36]
Former [2024/35]AT22.11.2023
CZ22.11.2023
DK22.11.2023
EE22.11.2023
ES22.11.2023
HR22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RO22.11.2023
RS22.11.2023
SE22.11.2023
SM22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/34]AT22.11.2023
DK22.11.2023
EE22.11.2023
ES22.11.2023
HR22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
SM22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/33]AT22.11.2023
DK22.11.2023
ES22.11.2023
HR22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
SM22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/26]AT22.11.2023
ES22.11.2023
HR22.11.2023
LT22.11.2023
LV22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/25]AT22.11.2023
ES22.11.2023
HR22.11.2023
LT22.11.2023
NL22.11.2023
PL22.11.2023
RS22.11.2023
SE22.11.2023
BG22.02.2024
NO22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/23]AT22.11.2023
ES22.11.2023
LT22.11.2023
NL22.11.2023
BG22.02.2024
GR23.02.2024
IS22.03.2024
PT22.03.2024
Former [2024/21]LT22.11.2023
NL22.11.2023
BG22.02.2024
GR23.02.2024
IS22.03.2024
Former [2024/20]GR23.02.2024
IS22.03.2024
Cited inInternational search[A]WO2016044770  (ABBVIE INC [US])
by applicantWO2016044770
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.